As of December 31, 2024, Argenx (ARGX) had approximately $3.4B in cash, cash equivalents and current financial assets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $761 from $717 at BofA
- Halozyme announces Vyvdura co-formulated with Enhanze granted MHLW approval
- Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment
- Argenx announces Japan MHLW approval for Vyvdura for CIDP
- Argenx price target raised to $723 from $639 at Wells Fargo